Chimerix, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The company's lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone919-806-1074
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$7.22 million
Profitability
Miscellaneous
Employees82
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable
Chimerix (NASDAQ:CMRX) Frequently Asked Questions
What is Chimerix's stock symbol?
Chimerix trades on the NASDAQ under the ticker symbol "CMRX."
How were Chimerix's earnings last quarter?
Chimerix Inc (NASDAQ:CMRX) issued its quarterly earnings data on Thursday, August, 8th. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.17) by $0.18. The biopharmaceutical company earned $1.44 million during the quarter, compared to analyst estimates of $2.30 million. Chimerix had a negative return on equity of 38.70% and a negative net margin of 729.02%. View Chimerix's Earnings History.
When is Chimerix's next earnings date?
What price target have analysts set for CMRX?
3 Wall Street analysts have issued 1-year price objectives for Chimerix's stock. Their predictions range from $2.00 to $7.00. On average, they anticipate Chimerix's share price to reach $4.00 in the next year. This suggests a possible upside of 158.9% from the stock's current price. View Analyst Price Targets for Chimerix.
What is the consensus analysts' recommendation for Chimerix?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chimerix in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Chimerix.
Has Chimerix been receiving favorable news coverage?
Media coverage about CMRX stock has trended somewhat negative on Tuesday, according to InfoTrie. The research group scores the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Chimerix earned a media sentiment score of -1.1 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Chimerix.
Are investors shorting Chimerix?
Chimerix saw a increase in short interest during the month of September. As of September 30th, there was short interest totalling 645,000 shares, an increase of 15.3% from the August 30th total of 559,400 shares. Based on an average daily trading volume, of 408,400 shares, the days-to-cover ratio is presently 1.6 days. Currently, 1.4% of the company's stock are sold short. View Chimerix's Current Options Chain.
Who are some of Chimerix's key competitors?
Some companies that are related to Chimerix include Arcus Biosciences (RCUS), AMAG Pharmaceuticals (AMAG), Aurinia Pharmaceuticals (AUPH), Syros Pharmaceuticals (SYRS), BioSpecifics Technologies (BSTC), Merus (MRUS), Obseva (OBSV), DURECT (DRRX), XBiotech (XBIT), Kiniksa Pharmaceuticals (KNSA), Lexicon Pharmaceuticals (LXRX), ImmunoGen (IMGN), Kadmon (KDMN), AC Immune (ACIU) and CytomX Therapeutics (CTMX).
What other stocks do shareholders of Chimerix own?
Who are Chimerix's key executives?
Chimerix's management team includes the folowing people:
- Mr. Timothy W. Trost, Sr. VP, CFO & Corp. Sec. (Age 61)
- Dr. William Garrett Nichols M.D., MS, Chief Medical Officer (Age 50)
- Mr. Michael A. Sherman, CEO & Pres (Age 53)
- Dr. Roy W. Ware Ph.D., MBA, Chief Manufacturing & Technology Officer
- Dr. Randall Lanier Ph.D., Chief Science Officer
How do I buy shares of Chimerix?
Shares of CMRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Chimerix's stock price today?
One share of CMRX stock can currently be purchased for approximately $1.55.
How big of a company is Chimerix?
Chimerix has a market capitalization of $94.66 million and generates $7.22 million in revenue each year. The biopharmaceutical company earns $-69,470,000.00 in net income (profit) each year or ($1.43) on an earnings per share basis. Chimerix employs 82 workers across the globe.View Additional Information About Chimerix.
What is Chimerix's official website?
How can I contact Chimerix?
Chimerix's mailing address is 2505 MERIDIAN PARKWAY SUITE 100, DURHAM NC, 27713. The biopharmaceutical company can be reached via phone at 919-806-1074 or via email at [email protected]
MarketBeat Community Rating for Chimerix (NASDAQ CMRX)
MarketBeat's community ratings are surveys of what our community members think about Chimerix and other stocks. Vote "Outperform" if you believe CMRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CMRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
